N Jewel Samadder1,2,3, Lisa Pappas1, Kenneth M Boucherr1,4, Ken R Smith1,4,5,6, Heidi Hanson1,6,7, Alison Fraser1,6, Yuan Wan1,6, Randall W Burt1,2,8, Karen Curtin1,6,9. 1. Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA. 2. Department of Medicine (Gastroenterology), University of Utah, Salt Lake City, Utah, USA. 3. Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona, USA. 4. Department of Medicine (Epidemiology), University of Utah, Salt Lake City, Utah, USA. 5. Department of Family and Consumer Studies, University of Utah, Salt Lake City, Utah, USA. 6. Utah Population Database, University of Utah, Salt Lake City, Utah, USA. 7. Department of Family and Preventive Medicine, University of Utah, Salt Lake City, Utah, USA. 8. Department of Oncological Sciences, University of Utah, Salt Lake City, Utah, USA. 9. Department of Medicine (Genetic Epidemiology), University of Utah, Salt Lake City, Utah, USA.
Abstract
OBJECTIVES: Colonoscopy is widely recommended for colorectal cancer (CRC) screening, but evidence to guide the optimal frequency of repeat screening examination is limited. We examined the duration and magnitude of the risk of developing CRC, following a negative colonoscopy in those at average risk and those with a first-degree family history of CRC. METHODS: A cohort of Utah residents aged 50-80 years who had a negative colonoscopy between 1 January 2001 and 31 December 2011 was identified using the Utah Population Database. Patients were followed from the time of the index colonoscopy until diagnosis of CRC, death, migration out of state, repeat colonoscopy, or end of the study period. CRC incidence after the index colonoscopy was compared with that of the state population by standardized incidence ratios (SIRs). RESULTS: A cohort of 131,349 individuals at average risk with a negative colonoscopy was identified. Compared with the state population, a negative colonoscopy was associated with SIRs of 0.15 (95% confidence interval (CI): 0.08-0.23) at 1 year, 0.26 (95% CI: 0.19-0.32) at 2-5 years, 0.33 (95% CI: 0.22-0.43) at 5-6 years, and 0.60 (95% CI: 0.44-0.76) at 7-10 years for CRC following the index colonoscopy. In a secondary analysis involving only patients with a first-degree relative with CRC, patients had a significantly lower incidence of CRC only for the first 5 years of follow-up (SIR 0.39, 95% CI: 013-0.64). There was also a difference in the risk of proximal (SIR 0.72, 95% CI: 0.45-0.98) and distal (SIR 0.51, 95% CI: 0.30-0.72) colon cancers at 7-10 years following a negative colonoscopy. CONCLUSIONS: The risk of developing CRC remains decreased for at least 10 years following the performance of a negative colonoscopy. However, the lower incidence of CRC in those with a family history of CRC differed in magnitude and timing being limited primarily to the first 5 years of follow-up and of lesser magnitude than that in the overall cohort.
OBJECTIVES: Colonoscopy is widely recommended for colorectal cancer (CRC) screening, but evidence to guide the optimal frequency of repeat screening examination is limited. We examined the duration and magnitude of the risk of developing CRC, following a negative colonoscopy in those at average risk and those with a first-degree family history of CRC. METHODS: A cohort of Utah residents aged 50-80 years who had a negative colonoscopy between 1 January 2001 and 31 December 2011 was identified using the Utah Population Database. Patients were followed from the time of the index colonoscopy until diagnosis of CRC, death, migration out of state, repeat colonoscopy, or end of the study period. CRC incidence after the index colonoscopy was compared with that of the state population by standardized incidence ratios (SIRs). RESULTS: A cohort of 131,349 individuals at average risk with a negative colonoscopy was identified. Compared with the state population, a negative colonoscopy was associated with SIRs of 0.15 (95% confidence interval (CI): 0.08-0.23) at 1 year, 0.26 (95% CI: 0.19-0.32) at 2-5 years, 0.33 (95% CI: 0.22-0.43) at 5-6 years, and 0.60 (95% CI: 0.44-0.76) at 7-10 years for CRC following the index colonoscopy. In a secondary analysis involving only patients with a first-degree relative with CRC, patients had a significantly lower incidence of CRC only for the first 5 years of follow-up (SIR 0.39, 95% CI: 013-0.64). There was also a difference in the risk of proximal (SIR 0.72, 95% CI: 0.45-0.98) and distal (SIR 0.51, 95% CI: 0.30-0.72) colon cancers at 7-10 years following a negative colonoscopy. CONCLUSIONS: The risk of developing CRC remains decreased for at least 10 years following the performance of a negative colonoscopy. However, the lower incidence of CRC in those with a family history of CRC differed in magnitude and timing being limited primarily to the first 5 years of follow-up and of lesser magnitude than that in the overall cohort.
Authors: Marcia L Feldkamp; John C Carey; Richard Pimentel; Sergey Krikov; Lorenzo D Botto Journal: Birth Defects Res A Clin Mol Teratol Date: 2011-08-24
Authors: Hermann Brenner; Jenny Chang-Claude; Christoph M Seiler; Alexander Rickert; Michael Hoffmeister Journal: Ann Intern Med Date: 2011-01-04 Impact factor: 25.391
Authors: Brian Bressler; Lawrence F Paszat; Zhongliang Chen; Deanna M Rothwell; Chris Vinden; Linda Rabeneck Journal: Gastroenterology Date: 2007-01 Impact factor: 22.682
Authors: Sampath Prahalad; Elizabeth O'brien; Alison M Fraser; Richard A Kerber; Geraldine P Mineau; David Pratt; David Donaldson; Michael J Bamshad; John Bohnsack Journal: Arthritis Rheum Date: 2004-12
Authors: Nancy N Baxter; Meredith A Goldwasser; Lawrence F Paszat; Refik Saskin; David R Urbach; Linda Rabeneck Journal: Ann Intern Med Date: 2008-12-15 Impact factor: 25.391
Authors: Bernard Levin; David A Lieberman; Beth McFarland; Kimberly S Andrews; Durado Brooks; John Bond; Chiranjeev Dash; Francis M Giardiello; Seth Glick; David Johnson; C Daniel Johnson; Theodore R Levin; Perry J Pickhardt; Douglas K Rex; Robert A Smith; Alan Thorson; Sidney J Winawer Journal: Gastroenterology Date: 2008-02-08 Impact factor: 22.682
Authors: Chyke A Doubeni; Sheila Weinmann; Kenneth Adams; Aruna Kamineni; Diana S M Buist; Arlene S Ash; Carolyn M Rutter; V Paul Doria-Rose; Douglas A Corley; Robert T Greenlee; Jessica Chubak; Andrew Williams; Aimee R Kroll-Desrosiers; Eric Johnson; Joseph Webster; Kathryn Richert-Boe; Theodore R Levin; Robert H Fletcher; Noel S Weiss Journal: Ann Intern Med Date: 2013-03-05 Impact factor: 25.391
Authors: Samir Gupta; David Lieberman; Joseph C Anderson; Carol A Burke; Jason A Dominitz; Tonya Kaltenbach; Douglas J Robertson; Aasma Shaukat; Sapna Syngal; Douglas K Rex Journal: Gastroenterology Date: 2020-02-07 Impact factor: 22.682
Authors: Samir Gupta; David Lieberman; Joseph C Anderson; Carol A Burke; Jason A Dominitz; Tonya Kaltenbach; Douglas J Robertson; Aasma Shaukat; Sapna Syngal; Douglas K Rex Journal: Gastrointest Endosc Date: 2020-02-07 Impact factor: 9.427
Authors: Jeffrey K Lee; Christopher D Jensen; Theodore R Levin; Ann G Zauber; Joanne E Schottinger; Virginia P Quinn; Natalia Udaltsova; Wei K Zhao; Bruce H Fireman; Charles P Quesenberry; Chyke A Doubeni; Douglas A Corley Journal: JAMA Intern Med Date: 2019-02-01 Impact factor: 21.873
Authors: Kai Wang; Wenjie Ma; Kana Wu; Shuji Ogino; Edward L Giovannucci; Andrew T Chan; Mingyang Song Journal: J Natl Cancer Inst Date: 2021-09-04 Impact factor: 11.816
Authors: Samir Gupta; David Lieberman; Joseph C Anderson; Carol A Burke; Jason A Dominitz; Tonya Kaltenbach; Douglas J Robertson; Aasma Shaukat; Sapna Syngal; Douglas K Rex Journal: Am J Gastroenterol Date: 2020-03 Impact factor: 12.045